Body area

Systemic / IV

Intravenous SVF is debated on safety and regulatory grounds, and human efficacy evidence remains insufficient.

Insufficient· Insufficient Evidence

What is IV SVF

It refers to delivering cells isolated from adipose tissue into the bloodstream rather than injecting a specific site.

Safety considerations

Reported concerns include thromboembolic events, cell distribution to the lungs, and laboratory quality control.

Several countries place intravenous SVF under strict oversight or permit it only within research settings.

Related conditions

Research in this area

Related clinical trials

  • NCT05334422

    SVF for Chronic Diabetic Foot Ulcers

    Chulalongkorn University · Thailand · Phase 1/2

  • NCT04771122

    SVF in Stage 3–4 Chronic Kidney Disease

    Kyoto Regenerative Institute · Japan · Phase 1

Latest PubMed research

5,220 indexed studies for this area (244 graded A/B) · auto-updated 17 August 2026

View all

Frequently asked questions